Last updated: 2026-10-13 03:49:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Vogenx Inc. (VOGX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $17.33, with a market capitalization of $260.86M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.95 to $38.41. This page covers its latest market performance, valuation, price trends and company information.
$260.86M | |
$18.12 | |
$38.41 | |
$12.95 | |
$17.56 | |
85.72K | |
185.09K | |
-- | |
$38.41 | |
$12.95 | |
-- | |
-- |
Vogenx Inc. (VOGX) last closed at $17.56 as of 2026-10-12 23:41:00, unchanged from the previous close of $17.56.
During the latest regular trading session, VOGX traded between $12.95 and $38.41, with a volume of 85.72K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Vogenx Inc. (VOGX) moved from $20.06 to $17.33, representing a decline of 13.61% ($2.73).
The stock traded between $14.56 and $24.24 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 99.39 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 17.2%
VOGX is currently trading at $17.33, placing it 17.2% of the way from its 52-week low of $12.95 to its 52-week high of $38.41. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vogenx Inc. (VOGX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.